697 results on '"Furuta, Takahisa"'
Search Results
2. Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders
3. Diagnostic criteria and endoscopic and histological findings of autoimmune gastritis in Japan
4. Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis
5. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
6. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel: Influence of alternate-day dosing of vonoprazan
7. Autoimmune gastritis induces aberrant DNA methylation reflecting its carcinogenic potential
8. Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
9. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
10. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
11. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
12. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia
13. Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis
14. Validation of a Teacher Educator Technology Competencies Survey
15. Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
16. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
17. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
18. Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
19. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker
20. Alopecia areata with autoimmune polyglandular syndrome type 3 showing type 1/Tc1 immunological inflammation
21. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
22. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
23. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
24. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
25. Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
26. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
27. The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
28. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin
29. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel
30. Four‐times‐daily Dosing of Rabeprazole with Sitafloxacin, High‐Dose Amoxicillin, or Both for Metronidazole‐Resistant Infection with Helicobacter pylori in Japan
31. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19
32. Statins directly suppress cytokine production in murine intraepithelial lymphocytes
33. Surveillance of patients with long-segment Barrettʼs esophagus: A multicenter prospective cohort study in Japan
34. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori.
35. Ability of Rabeprazole to Prevent Gastric Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype
36. Norepinephrine suppresses IFN-γ and TNF-α production by murine intestinal intraepithelial lymphocytes via the β1 adrenoceptor
37. The Impact of Generating Spontaneous Descriptions on Mental Model Development.
38. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study
39. Induction of Murine TNBS Colitis Is Strictly Controlled by a Modified Method Using Continuous Inhalation Anesthesia with Sevoflurane
40. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
41. Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial
42. Improvement of gastroesophageal reflux disease in Japanese patients with spinal kyphotic deformity who underwent surgical spinal correction†
43. A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study.
44. Impact of Interleukin-1β Genetic Polymorphisms on the Development of Hepatitis C Virus-Related Hepatocellular Carcinoma in Japan
45. Kyoto global consensus report on Helicobacter pylori gastritis
46. Influence of Prostate Stem Cell Antigen Gene Polymorphisms on Susceptibility to Helicobacter pylori-associated Diseases: A Case-control Study
47. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan
48. Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19
49. A Study on the Efficacy of Rebamipide for Patients with Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease
50. Does Rebamipide Prevent Gastric Mucosal Injury in Patients Taking Aspirin and Clopidogrel?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.